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Essentials
• Three dominant variants for the autosomal recessive bleeding disorder type-8 have been described. • To date, there has been no phenotype/genotype correlation explaining their dominant transmission.
• Proline plays an important role in P2Y12R ligand binding and signaling defects.
• P2Y12R homodimer formation is critical for the receptor function and signaling.
Summary. Background: Although inherited platelet disorders are still underdiagnosed worldwide, advances in molecular techniques are improving disease diagnosis and patient management. Objective: To identify and characterize the mechanism underlying the bleeding phenotype in a Caucasian family with an autosomal dominant P2RY12 variant. Methods: Full blood counts, platelet aggregometry, flow cytometry and western blotting were performed before next-generation sequencing (NGS). Detailed molecular analysis of the identified variant of the P2Y12 receptor (P2Y12R) was subsequently performed in mammalian cells overexpressing receptor constructs. Results: All three referred individuals had markedly impaired ADP-induced platelet aggregation with primary wave only, despite normal total and surface P2Y12R expression. By NGS, a single P2RY12:c.G794C substitution (p.R265P) was identified in all affected individuals, and this was confirmed by Sanger sequencing. Mammalian cell experiments with the R265P-P2Y12R variant showed normal receptor surface expression versus wild-type (WT) P2Y12R. Agonist-stimulated R265P-P2Y12R function (both signaling and surface receptor loss) was reduced versus WT P2Y12R. Critically, R265P-P2Y12R acted in a dominant negative manner, with agonist-stimulated WT P2Y12R activity being reduced by variant coexpression, suggesting dramatic loss of WT homodimers. Importantly, platelet P2RY12 cDNA cloning and sequencing in two affected individuals also revealed three-fold mutant mRNA overexpression, decreasing even further the likelihood of WT homodimer formation. R265 located within extracellular loop 3 (EL3) is one of four residues that are important for receptor functional integrity, maintaining the binding pocket conformation and allowing rotation following ligand binding. Conclusion: This novel dominant negative variant confirms the important role of
Introduction
The P2Y12 receptor (P2Y12R), a major G-proteincoupled receptor (GPCR) in platelets, is one of the two platelet receptors for ADP, stabilizing platelet aggregation and potentiating platelet activation initiated by many platelet agonists. Since its first observation [1] , P2Y12R deficiency (MIM #609821) has been identified as an autosomal recessive disorder characterized by mild to moderate mucocutaneous bleeding and excessive bleeding in response to trauma or after surgery [2] . Over the years, different gene alterations affecting P2Y12R function leading to platelet dysfunction have been reported, although such variations are relatively rare. P2Y12R defects can be associated with loss of expression (quantitative disorder) or loss of function (qualitative disorders). Rare naturally occurring loss-offunction variants in the P2RY12 gene offer a powerful approach with which to determine the P2Y12R structurefunction relationships with receptor variations that are able to be studied in native cells, such as platelets, from affected individuals. Clinical evaluation of affected individuals also provides insights into the biological consequences of P2Y12R dysfunction. To date, a series of function-disrupting mutations have been identified and shown to affect multiple aspects of platelet P2Y12R function, including surface receptor expression, ligand binding, G-protein coupling, receptor internalization, and receptor sorting (reviewed in [3] and [4] ). In 2007, Remijn et al. reported the first P2RY12 dominant mutation within the receptor extracellular loop (EL) 2 in a patient with abnormal ligand binding [5] . Soon after this, another dominant mutation was reported at the junction between transmembrane domain (TM) 6 and EL3 in a patient with normal ligand binding but abnormal function (impaired signaling) [6] , and more recently a dominant mutation affecting the PDZ-binding domain, which is critical for receptor recycling, was found [7] . However, the mechanism whereby the phenotype is correlated with the genotype is still unknown.
All class A GPCRs, including P2Y12R, share a similar structure, comprising one extracellular N-terminal domain, one intracellular C-terminal domain, and multiple TMs and ELs [8] . The ability of GPCRs to form dimers/oligomers is widely accepted, although their functional significance, especially in vivo, remains controversial [9] [10] [11] [12] . We have recently demonstrated that two loss-of-function variants of another plateletexpressed GPCR, the thromboxane receptor TPa, show aberrant homodimer formation, and this might represent one molecular mechanism through which platelet TPa dysfunction affects patient(s) carrying these mutations [13] .
In this study of a Caucasian family with an inherited bleeding disorder, we identified a P2RY12 mutation, predicting an arginine to proline (R265P) substitution within EL3. We assessed the impact of this variant on P2Y12R function in both platelets from affected individuals and cell lines, and highlight a potentially important role of P2Y12R homodimerization in receptor signaling.
Materials and methods

Patients
The Caucasian family described participated in a human research ethics committee-approved study using a gene panel to identify mutations associated with inherited platelet disorders (IPDs). All individuals provided written informed consent, and research was conducted in accordance with the Declaration of Helsinki.
Genetic studies
DNA was extracted from buffy coats with the salting-out method. Genotyping was performed with the Illumina Miseq platform according to the manufacturer's instructions and a designed panel of 32 platelet genes (Illumina, Scoresby, Victoria, Australia). Pathogenic variants or variants of uncertain significance were confirmed by Sanger sequencing. P2RY12 exon 2 sequencing was performed with the forward primer 5 0 -GGGCTAAGATTCTCTCTGTTGTC-3 0 and the reverse primer 5
0 -GCGCTTTGCTTTAACGAGTTCTG-3 0 , with BioTaq DNA polymerase (Bioline, Lane Cove, NSW, Australia). The sequence of the amplified fragment was obtained by capillary electrophoretic sequencing (AGRF, Sydney, NSW, Australia).
Platelet light transmission aggregometry (LTA)
Platelet-rich plasma (PRP) was prepared and agonistinduced LTA was performed on a four-channel aggregometer (Chrono-Log Corporation, Haverton, PA, USA) as previously described [14] and following the ISTH-SSC recommendations for the standardization of LTA [15] .
Platelet surface receptor expression and platelet activation measurement by flow cytometry Flow cytometry was performed on a four-color FACScalibur flow cytometer (BD Biosciences, North Ryde, NSW, Australia) with antibodies from BD Biosciences or Beckman Coulter (Lane Cove, NSW, Australia). Platelet surface glycoprotein expression levels were measured in EDTA PRP with a two-step antibody labeling technique: either mouse immunoglobulins or specific mouse mAbs were incubated with PRP samples for 15 min at room temperature, before the addition of Alexa Fluor 488-conjugated secondary goat anti-mouse IgG (Thermofisher, Scoresby, Victoria, Australia) for a further 15 min of incubation at room temperature. Platelet surface expression levels of P-selectin (CD62P), a marker of a-granule release, Pac-1 antibody binding, a marker of fibrinogen receptor activation (Pac-1 recognizes an epitope on activated a IIb b 3 complexes at, or near the fibrinogen-binding site) and platelet-monocyte aggregates were measured as previously described, with or without ADP [16] . Data from 10 000 events were collected in a logarithmic mode for platelets and in a linear mode for leukocytes, and analyzed with CELLQUEST software (BD Biosciences). In experiments assessing P2Y12R surface expression, washed platelets were prepared and fixed, and then labeled with primary anti-P2Y12 (1 : 75) or anti-docking protein 6 (negative control) antibodies, followed by the fluorescent secondary Alexa Fluor 647-conjugated antibody (1 : 200). Surface P2Y12R levels were quantified in terms of geometric mean fluorescence intensity from a gated population of 10 000 platelets after accounting for non-specific binding in negative controls. The data displayed represent the mean of three replicates.
Western blotting
Platelet lysates were prepared, and platelet western blotting experiments were conducted as previously described [17] . Briefly, platelet lysate proteins were separated by SDS-PAGE, and subsequently transferred onto a nitrocellulose membrane. After being blocked in 5% bovine serum albumin, membranes were labeled overnight with the primary antibodies rabbit polyclonal anti-P2Y12 (Novus Biologicals, Abingdon, UK) and mouse monoclonal anti-a-tubulin (Sigma-Aldrich, Gillingham, UK), diluted 1 : 500 and 1 : 10 000, respectively. Bands were detected with appropriate secondary horseradish peroxidase-conjugated antibodies and chemiluminescence (inhouse reagents). Densitometry measurements were performed by use of the Chemidoc XRS system with IMAGE-LAB software (Bio-rad, Gladesville, NSW, Australia). All images were obtained within the linear range of detection.
Platelet P2RY12 cDNA cloning Platelets were purified from EDTA-anticoagulated peripheral blood and lysed in Trizol (Life Technologies, Mulgrave, Victoria, Australia). Total mRNAs were extracted according to the manufacturer's protocol.
The total cDNAs were generated with the High-Capacity cDNA Reverse Transcription Kit (Life Technologies), and specific P2RY12 exon 2 PCR was performed. The PCR product was purified and cloned into the pGEMt vector (Promega, Alexandria, NSW, Australia) for amplification before Sanger sequencing of individual colonies.
Radioligand binding in transfected cell lines P2Y12R surface expression was determined by ligand binding with [ 3 H]2MeS-ADP (3 Ci mmol -1 ; 1 nM to 10 mM), as previously described [6, 7] .
Construction of P2Y12R constructs
Hemagglutinin (HA)/FLAG-tagged P2Y12R constructs were generated as previously described [18] . The R265P
and R265W mutations were generated with a Stratagene Quick Change Site-Directed Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA) by PCR amplification. DH5a cells were used for transformation, ampicillin-resistant colonies were amplified, and the correct sequence was confirmed by Sanger sequencing.
Cell culture
Human HEK293 cells were transiently transfected (5 lg per 100-mm dish) with N-terminally tagged wild-type (WT) P2Y12R or specific variants (R265P and R265W), as previously described [6] . In cotransfection studies, cells were transfected with equivalent levels of HA-tagged (5 lg per 100-mm dish) or FLAG-tagged receptor construct (5 lg per 100-mm dish). Receptor expression was assessed by radioligand binding, western blotting, and ELISA, as previously described [19] .
Expression and internalization of HA/FLAG-tagged P2Y12R constructs
Surface receptor expression was measured in non-permeabilized cells, and total receptor expression was assessed in permeabilized cells (0.1% Triton X-100; 30 min) with an anti-HA (HA-11) or anti-FLAG (M2) mAb. ADP-dependent tagged surface receptor loss was assessed by ELISA as described previously [19] .
P2Y12R function
WT and mutant receptor functions were measured as previously described [18] . Briefly, transfected cells were incubated with 1 lM forskolin (Sigma-Aldrich) to increase basal cAMP levels in the absence or presence of increasing concentrations of ADP (0.1 nM to 10 lM). cAMP levels were subsequently determined with a cAMP Enzyme Immunoassay Kit, according to the manufacturer's instructions (Sigma-Aldrich).
Impact of R265P on the receptor conformation
Visualization of the P2Y12R crystal structure (Protein Data Bank [PDB] code: 4pxz <PMID:24784220>) was carried out with PYMOL (Schroedinger, LLC).
Results
A Caucasian family (Fig. 1A ) of northern European heritage consisting of a father (II.2) and his two children (III.3 and III.4) was referred to us for investigation of an autosomal dominant platelet disorder. They all reported lifelong epistaxis, bruising, and abnormal bleeding from minor wounds. The proband (II.2) suffered from severe bleeding following colon polypectomy, which required large-volume transfusion and tranexamic acid (TA) to stabilize. His son (III.3) also experienced significant bleeding following circumcision requiring compression and TA. The daughter (III.4) has not reached puberty and has not had surgery. Full blood counts and stained blood films were unremarkable for the proband (II.2) and his children (III.3 and III.4). All three had normal platelet counts, normal coagulation screening test results, and normal plasma levels of fibrinogen factor VIII and von Willebrand factor (VWF), excluding a coagulation defect or VWF-dependent defect of primary hemostasis. The calculated bleeding scores obtained with the ISTH/SSC bleeding assessment tool [20] were 9 for II.2, 6 for III.3, and 4 for III.4.
Identification of a novel P2RY12 G794C mutation
Next-generation sequencing revealed a non-synonymous single G794C substitution on P2RY12, leading to an R265P substitution that was present in father and children and confirmed by Sanger sequencing (Fig. 1B) (BankIt2020574-NM_022788.3-MF182351).
The PredictSNP server using six tools for computational annotation gave a damaging prediction score of 87%.
Subsequently, more family members were tested, and the proband's father (I.2) was identified as the carrier (Fig. 1A) . Interestingly, he had his first operation recently when he underwent open heart surgery, which did not lead to any serious bleeding after he had received highdose TA preoperatively.
Platelet function studies
LTA performed on all four carriers (I.2, II.2, III.3, and III.4) revealed a severe deficit in ADP-stimulated platelet aggregation (primary wave only) and reduced aggregation in response to collagen, epinephrine, and thrombin receptor-activating peptide, with disaggregation at lower concentrations ( Fig. 1C,D ; Table 1 ). Following ADP activation, platelet a-granule release was reduced as measured by P-selectin exposure and platelet-monocyte aggregate formation; binding of the activated a IIb b 3 antibody Pac-1 was also reduced as compared with control representing the lowest percentiles of the normal range (Fig. 1F ).
R265P-P2Y12R expression
Platelet surface expression of P2Y12R was similar in the proband (II.2) and control as measured by flow cytometry ( Fig. 2A) . Similarly, the total platelet content was also normal following western blotting experiments (Fig. 2B) . The specificity of the P2Y12R antibody used in these studies was validated by using HEK293 cells transfected with FLAG-tagged P2Y12R in both our flow cytometry and western blotting studies (Fig. 2) .
R265P-P2Y12R impairs signaling in a dominant negative manner
Further detailed study was undertaken in cells expressing tagged WT and variant receptor constructs. Initial studies assessed whether R265P-P2Y12R and WT P2Y12R were expressed at comparable levels at the cell surface. Equivalent concentrations of HA-tagged variant or FLAGtagged WT receptor cDNA were transiently transfected into HEK293 cells. Total expression of R265P-P2Y12R as assessed by ligand binding was similar to that of WT P2Y12R and that of the related P2Y12R variant R265W (Fig. 3A) . Further analysis by ELISA was also undertaken to assess FLAG-tagged WT or HA-tagged R265P variant expression. Total receptor expression levels, as assessed in permeabilized HEK293 cells, were comparable between WT P2Y12R and R265P-P2Y12R (Fig. 3B) . Surface receptor expression levels, as assessed in non-permeabilized cells, were also equivalent between WT P2Y12R and R265P-P2Y12R (Fig. 3B) . Western blotting of cell lysates also revealed comparable total expression of FLAG-tagged WT P2Y12R and HA-tagged R265P-P2Y12R (Fig. 3C) . Given the comparable levels of total and surface receptor expression, agonist-stimulated receptor function was assessed. Notably, with ADP, the inhibition of forskolin-stimulated adenylyl cyclase (AC) activity (Fig. 3D,E) was significantly attenuated for R265P-P2Y12R versus WT P2Y12R. The activity of the related P2Y12R R265W variant was also reduced, although not to the same extent as that of R265P-P2Y12R (Fig. 3D) . ADP promotes agonist-stimulated P2Y12R internalization [20] , and is therefore another functional readout of receptor activity. Again, ADP-stimulated surface receptor loss was significantly attenuated in R265P-P2Y12R variant versus WT P2Y12R. In the current study and in previous studies by ourselves [6, 21] and others, [5] there has been significant impairment of receptor function even in patients who heterologously express mutant P2Y12R variants. The loss of function in these patients is often surprising, as they should still express a WT copy of receptor that one would predict could still support normal receptor function. We therefore examined in this study whether R265P-P2Y12R had the potential to act as dominant negative mutant reducing WT P2Y12R activity when they were coexpressed. Initial ELISA (Fig. 3B ) and western blotting ( Fig. 3C ) studies confirmed that when cotransfection with equivalent levels of cDNA was performed, there were comparable levels of R265P-P2Y12R and WT P2Y12R expression. Therefore coexpression of R265P-P2Y12R had no apparent effect on either surface or total WT P2Y12R expression. Intriguingly, at a functional level (agonist-dependent signaling [ Fig. 3E ] or loss of surface expression [ Fig. 3F ]), the deficit in R265P-P2Y12R function was not rescued by WT P2Y12R cotransfection, suggesting a dominant negative phenotype. Indeed, ADPstimulated receptor function ( Fig. 3D and E) was equivalent to that of R265P-P2Y12R alone.
P2RY12 expression in affected individuals
P2RY12 cDNAs from patients I.2 and II.2 were cloned and sequenced. Surprisingly, only four of 21 clones for I.2 and six of 18 for II.2 were found to be WT (average of 25%), the majority being mutant (75%) (Fig. 4A) . Dimerization plays an important role in P2Y12R function; from the cDNA data, we predicted that the amounts of the different homodimers and WT dimers only represented < 10% of the total (Fig. 4B ).
P2Y12R three-dimensional (3D) modeling
Protein modeling suggests that the amide proton of R265 forms a hydrogen bond with the carbonyl oxygen of residue 261 (as is normal in a helix). The Q263 side chain makes direct contact with the terminal phosphate group of the ligand (Fig. 4C) . In an R265P mutant, the hydrogen bond to residue 261 will be unable to form, because the proline does not have an amide proton. As a consequence, the mutation could destabilize this end of helix H6, and thereby not only affect the ligand-binding pocket by affecting the positioning of E263, but also prevent the normal docking of the ligand between the TMs and consequently impact on normal receptor signaling. In contrast, mutation to tryptophan (R265W) does not cause the same degree of disruption, with the 261-265 hydrogen bond still being able to form. The nature of the side chain on the tryptophan is significantly different from that of the native arginine side chain, however, resulting in a milder phenotype.
Discussion
IPDs caused by P2RY12 variants are characterized by a lifelong history of excessive bleeding, prolonged bleeding times, and severely impaired platelet aggregation responses to ADP. After the first P2RY12 variant description, the assumption was that heterozygous carriers were asymptomatic, until there were reports of three dominant variants [5, 6, 22] ; however, the mechanism behind the different genotype-phenotypes correlation has not been elucidated. In a Caucasian family, we identified a new dominant negative P2RY12 variant that was responsible for severe bleeding requiring transfusion following minor surgical procedures. We confirmed the role of P2Y12R EL3 in receptor signaling and the importance of the residue at position 265. Using a cell-based model, we have reproduced the dominant negative phenotype, and we propose a mechanism linking the genotype to the phenotype.
Despite P2RY12 variants being rare, the identification of them has helped to identify functionally important regions of this GPCR. Loss-of-function variations in EL2 TM5 are associated with abnormal ligand binding [6, 23] , whereas variations in EL3 TM6, despite normal ligand binding, are associated with abnormal receptor function suggestive of these regions' role in signal transduction [24] . Intracellular regions including EL2 and the extreme C-terminus are associated with changes in receptor activity [18] and trafficking [7] (Fig. 4D) . In 2003, Cattaneo et al. reported a patient with a lifelong history of easy bruising and bleeding who was a compound R256Q/ R265W heterozygote with normal platelet P2Y12R expression but impaired function. Two asymptomatic offspring of the proband inherited R265W-P2Y12R alone, and their platelets showed reduced aggregation in response to low-dose ADP [2] . Hoffman et al. showed that, when substituted, P2Y1R R287, which is equivalent to P2Y12R R265, induced a > 1000-fold shift in EC50, and suggested that R287 may be involved in an ionic bridge between EL2 and EL3 that is crucial for receptor activation [25] . Further data supporting the importance of R265 in P2Y12R were recently obtained in yeast by Ignatovica et al., who showed the importance of residues in the E181, R256 and R265 positions in maintaining the function of P2Y12R [26] , although the observed EC50 changes were more modest than in our current study. Zhang et al. have shown that R265 P2Y12R variations impairing activation impact on the conformational states of the receptor, rather than on ligand binding [27] .
The family described in this article reported lifelong easy bruising, and the father and his son (II.2 and III.3), following surgical procedures, suffered serious bleeding that only stopped after blood transfusion and TA administration for the father, and a combination of compression and TA administration for his young son. Platelet aggregation in reponse to ADP was markedly impaired in all carriers. Both surface and total expression levels of P2Y12R were comparable with that from platelets taken from healthy controls. Heterologous expression of FLAG-tagged WT P2Y12R and HA-tagged R265P-P2Y12R in HEK293 cells confirmed our platelet studies, with comparable surface and total expression. Importantly, although ligand binding to R265P-P2Y12R was found not to be affected, receptor signaling as assessed by inhibition of forskolin-stimulated AC activity was impaired. Our data also support earlier studies showing the lower impact of the R265W mutation [3] than of the R265P mutation on receptor signaling. Following binding, ligand docking between the TMs is critical for receptor-mediated signaling, with a stable salt bridge between E188 and R256 linking TM5 and TM6 stabilized by a hydrogen bond between Q195 and T260 [28] . The X-ray crystal structure of P2Y12R bound to 2MeS-ADP shows hydrogen bonds between R265 and L261 (Fig. 4C) , and between Q263 and the ligand [27] . The R265P substitution would disrupt the former hydrogen bond and destabilize the C-terminus of helix H6, thereby probably affecting the ligand-binding pocket by repositioning Q263, and in turn impairing receptor signaling. Dimerization of GPCRs plays an important role in their function [9] [10] [11] [12] , as demonstrated by clopidogrel, a platelet P2Y12R antagonist and antithrombotic agent, interfering with homo-oligomeric assembly of P2Y12R and inhibiting localization of these complexes into the lipid rafts required for receptor activation [29] . An important finding of our study is the disruption of WT P2Y12R function by coexpression with R265P-P2Y12R when the receptors were expressed at equivalent levels. Future detailed studies with increasing levels of WT P2Y12R are planned to assess at which point excess WT P2Y12R can effectively overcome the dominant negative effect of R265P-P2Y12R, and the role that receptor oligomerization may play in this process.
Platelet mRNA studies have also shown overexpression of the mutant allele in I.2 and II.2, resulting in a marked decrease in the level of WT homodimers, and suggesting differential allelic expression [30] ; however, we cannot exclude the possibility of preferential expression or increased mRNA survival as a driver for the increase in mutant mRNA [31] . Imprinted genes are normally monoallelically expressed, so in our family the three-fold increase in mutant mRNA as compared with WT mRNA would favor differential allelic expression rather than imprinting. Our mRNA study showed significantly increased expression of the same mutant allele in the two heterozygous individuals tested, and this is probably also the case in both children. However, differential allelic expression is often associated with variation in transmission of some diseases [30] , which has not been observed in this family, and this would suggest increased mutant mRNA survival further enhancing the dominant phenotype.
In conclusion, recent improvements in high-throughput sequencing technologies led to the identification of a novel dominant R265P P2RY12 variant in a family with absence of irreversible ADP-induced platelet aggregation and severe postsurgical bleeding requiring transfusion and TA.
As shown by 3D modeling, R265 helps to maintain the correct EL3 structure, which is important for ligand docking and receptor signaling. Our report further highlights the important role of receptor homodimerization in ADP-P2Y12R signaling, and helps to explain the dominant negative phenotype observed in patients [5, 6, 22] . 
